You can find here below the scientific program and relevant abstracts of our past events:

• Osteoarthritis & Inflammation
• Reproduction
• Dermatology
• Endocrinology

For information please contact:

ECCEO 2006, March 15-18, Vienna, Austria
Saturday, March 18, 08.30-10.00

Download the full programme of the symposium on PDF format

• Mechanisms of action of hyaluronic acid
  Chevalier (France)
• Efficacy of hyaluronic acid in knee OA: placebo-controlled and comparative studies
  E. Maheu (France)
• Hyaluronic acid in other osteoarthritic joints: hip, thumb, shoulder and ankle
  V. Legré (France)
• Data driven recommendations for the performance of intra-articular knee injections
  T. Boyer (France)
• Overall tolerability and analgesic activity of Sinovial in the treatment of knee OA
  P. Brühlmann (Switzerland)

EULAR 2006, June 21-24, Amsterdam, The Netherlands
Friday, June 23, 08.15-09.45

Download the full programme of the symposium on PDF format

• Re-evaluation of the current guidelines for the registration of structure-modifying drugs in osteoarthritis
  J.-Y. Reginster (Belgium)
• Cartilage protection: How to assess? What’s the evidence?
  B.A. Michel (Switzerland)
• STOPP (STudy on Osteoarthritis Progression Prevention): “A new two-year trial with chondroitin 4&6 sulfate(CS)"
  Study design according to OA guidance - A. Kahan (France)
  Clinical results - J.-Y. Reginster (Belgium)
  Radiological results - E. Vignon (France)

OARSI 2006, December 7-10, Prague, Czech Republic
Friday, December 8, 12.30-14.00

Download the full programme of the symposium on PDF format

ISGE 2006, March 2-5, Florence, Italy
Thursday, March 2, 14.00-16.00

Download the full programme of the symposium on PDF format

• Bioactivity of the HP urinary FSH (Fostimon®) versus the
  recombinant FSH (Gonal-F) evaluated by the follicle bioassay
  R. Cortvrindt (Belgium)
• What’s the principle for selecting u-FSH or r-FSH in ART:
  recent clinical evidences in women undergoing controlled ovarian
  stimulation for IntraCytoplasmic Sperm Injection (ICSI)
  J. Urbancsek (Hungary)
• The choice between recombinant versus urinary gonadotrophins -
  impact on IVF-treatment costs in Germany
  K. Diedrich (Germany)
• In vitro fertilization in France: economic aspects and influence
  of the gonadotrophin choice (urinary versus recombinant) on cost
  J. de Mouzon (France)
• Cost influences the choice of gonadotrophins (urinary versus
  recombinant) used in ART treatment in the United Kingdom
  E. Iammarrone (UK)

Saturday, March 4, 14.00-16.00

Download the full programme of the symposium on PDF format

• The immuno-modulatory properties of Progesterone
  J. Szekeres-Bartho (Hungary)
• Progesterone support in assisted reproduction
  S. Daya (Canada)
• Progesterone benefits in IVF cycles: an issue of dose and way of administration
  D. de Ziegler (Switzerland)
• Progesterone use in recurrent miscarriage
  H. Carp (Israel)

MSRM 2006, April 27-29, Crete, Greece
Friday, April 28, 12.30-14.00

Download the full programme of the symposium on PDF format

• Human derived and recombinant gonadotrophins: an overview
  M. Filicori (Italy)
• Urinary FSH versus recombinant FSH in the treatment of older women
  C. Aragona / M. Mohamed (Italy)
• Pharmacoeconomic aspects of gonadotrophins choice
  J. de Mouzon (France)

ESHRE 2006, June 18-21, Prague, Czech Republic
Tuesday, June 20, 14.00-15.15

Download the full programme of the symposium on PDF format

• Nutrition and reproduction: physiological mechanisms
  D. T. Baird (UK)
• Biological and social determinants of obesity
  J. Collins (Canada)
• Fertility in obese women
  R. J. Norman (Australia)

ROYAN 2006, September 13-15, Tehran, Iran

MEFS 2006, November 15-17, Aqaba, Jordan

EADV 2006, October 4-8, Rhodes, Greece
Thursday, October 5, 17.45-19.15

Download the full programme of the symposium on PDF format

• The value of topical corticosteroids in psoriasis, their advantages and drawbacks
  J.P. Ortonne (France)
• Pharmacodynamics assessment of a new occlusive, ready to use, self-adhesive BMV formulation: vasoconstrictive, anti-inflammatory and anti-psoriatic activity
  S. Seidenari / G. Pellacani (Italy)
• Evaluation of specific clinical safety aspects of the new BMV medicated plaster formulation
  C. Queille-Roussel / J.P. Ortonne (France)
• Efficacy of the new BMV medicated plaster for treatment of chronic plaque psoriasis
  K. Peris (Italy)
• Current and future investigations
  L. Naldi (Italy)

ETA 2006, September 2-6, Naples, Italy
Monday, September 4, 15.30-16.30

Download the full programme of the symposium on PDF format